显示 1-6 共 6 条结果 关于 "GF38434754"
Steffen Rausch et al.
Urology, 85(1), 182-188 (2014-12-23)
To evaluate complications and functional outcome and to identify patient-associated risk factors, we analyzed consecutive patients undergoing thulium:yttrium-aluminum-garnet laser enucleation of the prostate (ThuLEP) in our department. A total of 234 patients were prospectively analyzed. Preoperative data, postoperative complications, and...
T Bach et al.
World journal of urology, 28(2), 163-168 (2010-03-06)
Tm:YAG 2 mum cw laser prostatectomy was introduced in the treatment of benign ptostatic obstruction (BPO). Since then numerous studies have been published proving efficacy during follow-up. However, different surgical techniques were introduced with different names for similar techniques that...
Li Li et al.
Journal of nanoscience and nanotechnology, 14(6), 4313-4319 (2014-04-18)
Lutetium oxide nanocrystals codoped with Tm3+ and Yb3+ have been successfully synthesized via adjusting the pH values of the precursor solution in a hydrothermal method followed by a subsequent calcination process. The samples were systematically characterized by X-ray diffraction, field-emission...
Giovanni Muto et al.
Urology, 83(4), 851-855 (2014-02-20)
To determine whether thulium:yttrium-aluminum-garnet laser resection of bladder tumor (TmLRBT) may offer advantages over classic resection. From April 2011 to September 2012, 55 consecutive patients newly diagnosed with clinical stage ≤T2 bladder cancer were enrolled in a prospective study on TmLRBT....
Amedeo Calisto et al.
Journal of neurosurgery. Pediatrics, 14(6), 563-572 (2014-10-18)
Hypothalamic hamartomas (HH) may induce drug-resistant epilepsy (DRE), thereby requiring surgical treatment. Conventionally, treatment is aimed at removing the lesion, but a disconnection procedure has been shown to be safer and at least as effective. The thulium laser (Revolix) has...
Kun Tang et al.
Journal of endourology, 28(1), 65-72 (2013-08-29)
To assess the efficacy and safety of thulium laser resection of the prostate (TmLRP) vs transurethral resection of the prostate (TURP) for treating patients with benign prostatic hyperplasia (BPH). A systematic search of the electronic databases, including Medline, Scopus, China...

社交媒体

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

科研、开发、生产。

作为生命科学行业的全球领先供应商,我们致力于为科研、生物技术开发和生产,以及制药药物疗法开发和生产提供各类解决方案和服务。

© 2021年版权归德国达姆施塔特默克集团(Merck KGaA)及/或其附属公司所有。版权所有。

未经许可,严禁复制本网站上的任何资料。